DK3412672T3 - Krystalform A af 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D]pyrimidin-4-amin som TLR7-agonist, fremstillingsfremgangsmåde og anvendelse deraf - Google Patents

Krystalform A af 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D]pyrimidin-4-amin som TLR7-agonist, fremstillingsfremgangsmåde og anvendelse deraf Download PDF

Info

Publication number
DK3412672T3
DK3412672T3 DK17747004.4T DK17747004T DK3412672T3 DK 3412672 T3 DK3412672 T3 DK 3412672T3 DK 17747004 T DK17747004 T DK 17747004T DK 3412672 T3 DK3412672 T3 DK 3412672T3
Authority
DK
Denmark
Prior art keywords
pyrrolo
pyrrolidin
pyrimidin
ylmethyl
butoxy
Prior art date
Application number
DK17747004.4T
Other languages
English (en)
Inventor
Zhaozhong Ding
Fei Sun
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Application granted granted Critical
Publication of DK3412672T3 publication Critical patent/DK3412672T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17747004.4T 2016-02-05 2017-02-04 Krystalform A af 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D]pyrimidin-4-amin som TLR7-agonist, fremstillingsfremgangsmåde og anvendelse deraf DK3412672T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610082029.8A CN107043379A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的晶型a、其制备方法和医药用途
PCT/CN2017/072891 WO2017133684A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的晶型a、其制备方法和用途

Publications (1)

Publication Number Publication Date
DK3412672T3 true DK3412672T3 (da) 2020-10-19

Family

ID=59499348

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17747004.4T DK3412672T3 (da) 2016-02-05 2017-02-04 Krystalform A af 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D]pyrimidin-4-amin som TLR7-agonist, fremstillingsfremgangsmåde og anvendelse deraf

Country Status (28)

Country Link
US (2) US10442811B2 (da)
EP (1) EP3412672B1 (da)
JP (1) JP6889171B2 (da)
KR (1) KR102393280B1 (da)
CN (2) CN107043379A (da)
AR (1) AR107548A1 (da)
AU (1) AU2017215801B2 (da)
CA (1) CA3013518C (da)
CL (1) CL2018002092A1 (da)
DK (1) DK3412672T3 (da)
EA (1) EA035951B1 (da)
ES (1) ES2830443T3 (da)
HK (1) HK1259170A1 (da)
HR (1) HRP20201644T1 (da)
HU (1) HUE051399T2 (da)
IL (1) IL260968B (da)
LT (1) LT3412672T (da)
MX (1) MX2018009501A (da)
NZ (1) NZ744884A (da)
PH (1) PH12018501643A1 (da)
PL (1) PL3412672T3 (da)
PT (1) PT3412672T (da)
SG (1) SG11201806683UA (da)
SI (1) SI3412672T1 (da)
TW (1) TWI754629B (da)
UA (1) UA121161C2 (da)
WO (1) WO2017133684A1 (da)
ZA (1) ZA201805186B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
KR20210013183A (ko) * 2018-05-25 2021-02-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Tlr7 작용제 및 폐암을 치료하기 위한 이의 약학 조합물
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
EP3937944A1 (en) * 2019-03-15 2022-01-19 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Toll-like receptor agonists for use in the treatment of hepatitis b
CN118045051A (zh) * 2019-04-23 2024-05-17 正大天晴药业集团股份有限公司 一种tlr7激动剂的固体药物组合物
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
JP2023536945A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Tlrアゴニスト
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
EP2670244B1 (en) * 2011-02-04 2018-04-11 Duquesne University of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) * 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
NZ705589A (en) * 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
WO2014081645A1 (en) * 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
EP2922550B1 (en) 2012-11-20 2017-04-19 Glaxosmithkline LLC Novel compounds
CR20160512A (es) 2014-05-01 2016-12-21 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7
EA032824B1 (ru) * 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途

Also Published As

Publication number Publication date
WO2017133684A1 (zh) 2017-08-10
MX2018009501A (es) 2018-12-11
CN108602831A (zh) 2018-09-28
EP3412672B1 (en) 2020-07-15
JP6889171B2 (ja) 2021-06-18
IL260968B (en) 2022-05-01
SG11201806683UA (en) 2018-09-27
US20200039988A1 (en) 2020-02-06
ZA201805186B (en) 2024-08-28
KR102393280B1 (ko) 2022-05-02
CN108602831B (zh) 2020-11-03
CA3013518A1 (en) 2017-08-10
KR20180104117A (ko) 2018-09-19
PL3412672T3 (pl) 2021-01-25
HUE051399T2 (hu) 2021-03-01
LT3412672T (lt) 2020-11-10
PT3412672T (pt) 2020-11-11
EP3412672A4 (en) 2019-07-17
AU2017215801B2 (en) 2020-09-10
PH12018501643A1 (en) 2019-06-03
CL2018002092A1 (es) 2018-12-07
TWI754629B (zh) 2022-02-11
CN107043379A (zh) 2017-08-15
UA121161C2 (uk) 2020-04-10
HK1259170A1 (zh) 2019-11-29
BR112018015880A2 (pt) 2018-12-26
AR107548A1 (es) 2018-05-09
EP3412672A1 (en) 2018-12-12
ES2830443T3 (es) 2021-06-03
US10947245B2 (en) 2021-03-16
CN108602831B9 (zh) 2020-12-04
JP2019505533A (ja) 2019-02-28
EA035951B1 (ru) 2020-09-04
TW201728589A (zh) 2017-08-16
US20190040071A1 (en) 2019-02-07
CA3013518C (en) 2022-07-19
HRP20201644T1 (hr) 2020-12-25
EA201891768A1 (ru) 2019-01-31
NZ744884A (en) 2022-09-30
US10442811B2 (en) 2019-10-15
SI3412672T1 (sl) 2021-02-26
AU2017215801A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
DK3412672T3 (da) Krystalform A af 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D]pyrimidin-4-amin som TLR7-agonist, fremstillingsfremgangsmåde og anvendelse deraf
DK3429591T3 (da) Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse
DK3321265T3 (da) 4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer
DK3233863T3 (da) Kondenserede ringheteroarylforbindelser og anvendelse deraf som trk-hæmmere
DK3555070T3 (da) Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
EP3310339A4 (en) OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHOD OF USE THEREOF AND METHOD OF PRODUCTION THEREOF
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
EP3146774A4 (en) Fine timing measurement positioning and improvements in wireless local area networks
DK3143011T3 (da) Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
DK3412674T3 (da) Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser
DK3154950T3 (da) N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte
DK3412671T3 (da) TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former
EP3508481A4 (en) CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME
DK3412673T3 (da) Fremgangsmåde til fremstilling af pyrrolo[3,2-D]pyrimidin-forbindelse og mellemprodukter deraf
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
EP3255046A4 (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
DK3487851T3 (da) Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer
EP3724162C0 (en) INTERMEDIATES FOR OPTICALLY ACTIVE PIPERIDINE DERIVATIVES AND METHODS OF PREPARATION THEREOF
DK3347106T3 (da) Modificering af naturfjer til anvendelse i sportsartikler
DK3652148T3 (da) Amorf form af vilanterol-trifenatat samt fremgangsmåde til fremstilling deraf
DK3555048T3 (da) Nye picolinsyrederivater og deres anvendelse som mellemprodukter